Pain is a complex, multidimensional process that negatively affects physical and mental functioning, clinical outcomes, quality of life, and productivity for cystic fibrosis (CF) patients. CF is an inherited multi-system disease that requires a complete approach in order to evaluate, monitor and treat patients. The landscape in CF care has changed significantly, with currently more adult patients than children worldwide. Despite the great advances in supportive care and in our understanding regarding its pathophysiology, there are still numerous aspects of CF pain that are not fully explained. This review aims to provide a critical overview of CF pain research that focuses on pain assessment, prevalence, characteristics, clinical association and the impact of pain in children and adults, along with innovative nanotechnology perspectives for CF management. Specifically, the paper evaluates the pain symptoms associated with CF and examines the relationship between pain symptoms and disease severity. The particularities of gastrointestinal, abdominal, musculoskeletal, pulmonary and chest pain, as well as pain associated with medical procedures are investigated in patients with CF. Disease-related pain is common for patients with CF, suggesting that pain assessment should be a routine part of their clinical care. A summary of the use of nanotechnology in CF and CF-related pain is also given. Further research is clearly needed to better understand the sources of pain and how to improve patients’ quality of life.

Prophylactic paracetamol administration impacts vaccine immune response; this study (www.clinicaltrials.gov: NCT01235949) is the first to assess PHiD-CV immunogenicity following prophylactic ibuprofen administration. In this phase IV, multicenter, open-label, randomized, controlled, non-inferiority study in Romania (November 2010–December 2012), healthy infants were randomized 3:3:3:1:1:1 to prophylactically receive immediate, delayed or no ibuprofen (IIBU, DIBU, NIBU) or paracetamol (IPARA, DPARA, NPARA) after each of 3 primary doses (PHiD-CV at age 3/4/5 months co-administered with DTPa-HBV-IPV/Hib at 3/5 and DTPa-IPV/Hib at 4 months) or booster dose (PHiD-CV and DTPa-HBV-IPV/Hib; 12–15 months). Non-inferiority of immune response one month post-primary vaccination in terms of percentage of infants with anti-pneumococcal antibody concentrations ≥0.2 µg/mL (primary objective) was demonstrated if the upper limit (UL) of the 98.25% confidence interval of difference between groups (NIBU vs IIBU, NIBU vs DIBU) was <10% for ≥7/10 serotypes. Immunogenicity and reactogenicity/safety were evaluated, including confirmatory analysis of difference in fever incidences post-primary vaccination in IBU or DIBU group compared to NIBU. Of 850 infants randomized, 812 were included in the total vaccinated cohort. Non-inferiority was demonstrated for both comparisons (UL was <10% for 9/10 vaccine serotypes; exceptions: 6B [NIBU], 23F [IIBU]). However, fever incidence post-primary vaccination in the IIBU and DIBU groups did not indicate a statistically significant reduction. Prophylactic administration (immediate or delayed) of paracetamol decreased fever incidence but seemed to reduce immune response to PHiD-CV, except when given only at booster. Twenty-seven serious adverse events were reported for 15 children; all resolved and were not vaccination-related.

Childhood obesity is a leading public health concern because it represents a risk factor for many comorbid conditions in youth, such as cardiovascular disease, metabolic syndrome and sleep apnea. The purposes of the study were to evaluate the effect of the program at 6 months after the first visit and determine the predictive factors. We realised a retrospective study that included 69 obese children and adolescent, boys and girls, followed-up at Saint Mary Children�s Hospital and Regional Center of Diagnosis, Counselling and Monitoring of Overweight and Obese Children from �Grigore T. Popa� University of Medicine and Pharmacy Iasi, Romania, aged 12 to 18 years. The patients were included in two groups: group 1 included 38 patients receveived a hypocaloric diet only and group 2 included 31 patients received a hypocaloric diet associated with kinetotherapy and psychoterapy. We evaluated the body mass index, total cholesterol and tryglicerides before and after treatment. Our results confirm that diet and physical activity affects significantly the serum lipid profile. In this context, decreasing obesity in children through diet and exercise should be an important strategy for preventing cardio-metabolical disease in adult.

Rationale:Collodion baby is a rare autosomal recessive disorder. It can be the first expression of some forms of ichthyosis.Patient concerns:The authors present the case of a newborn diagnosed with severe Collodion baby syndrome who required prolonged hospitalization in the intensive care unit because of infectious complications like the fungal sepsis and other bacterial superinfections.Diagnoses:The case has many diagnostic and therapeutic particularities and management difficulties. Skin culture, dermatological and genetic exam were required.Interventions:The treatment required multidisciplinary involvement: neonatologist, pediatrician, geneticist, dermatologist, psychologist, ophthalmologist, audiologist.Outcomes:The evolution during hospitalization was slowly favorable, but later, after a few months, it developed some complications.Lessons:In our case, skin injuries, total parenteral nutrition, aggressive and prolonged antibiotic therapy, intravenous devices, high hospitalization duration were risk factors for colonization and sepsis with fungi, especially in the neonatal period, sometimes with severe evolution and prognosis.

Novel materials belonging to the class of anionic clays are synthesized by investigating their properties at nano scale. Thus, hydrotalcites or layered double hydroxides (LDHs) were used as drug delivery carriers in order to prevent or to treat infections produced by some pathogen agents. Their physical and chemical properties allow them to include different molecules in the interlayer space and then to ensure their transport to the target. The current work reveals the obtaining of nanohybrid compounds type amoxicillin/clavulanic acid-layered double hydroxides (Amox/CA-LDHs) followed by structural and morphological characterization of these nanostructures for future applications as drug controlled release systems. IR spectroscopy and Scanning Electron Microscopy pointed out LDHs ability to incorporate the medicines without modification of therapeutic activity.